Bionomics
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WABionomics Limited (BNO) is a biopharmaceutical company focused on the discovery and development of novel drug candidates focused on the treatment of central nervous system disorders such as anxiety, depression and Alzheimer's Disease.
Bionomics' lead drug candidate BNC210 (currently in Phase 2 for the treatment of agitation) is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co Inc.
Contact Details
31 Dalgleish Street, THEBARTON SA 5031
08 8354 6100
Lists and Charts
Share Price
Closing price for the last 90 trading days
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 855th |  | Bionomics | $5.5m |
| 999th | | Powerhouse Ventures | $1.1m |
| 1000th | | Spenda | $1.1m |
| 1003rd |  | Registry Direct | $1.1m |
| 1004th | | Naos Emerging Opportunities Company | $1.1m |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Company Activity
| NEW ROLE: Connor Bernstein, | 01 Mar 2022 |
| NEW ROLE: Liz Doolin, | 25 Aug 2021 |
| NEW ROLE: Suzanne Irwin, Company Secretary | 11 Aug 2021 |
| NEW ROLE: Miles Davies, Non-Executive Director | 11 Aug 2021 |
| NEW ROLE: Jens Mikkelsen, | 24 Nov 2020 |
| NEW ROLE: Stephen Birrell, Chief Financial Officer | 24 Nov 2020 |
| NEW ROLE: Steven Lydeamore, Chief Financial Officer | 24 Nov 2020 |
| NEW ROLE: Paul Rolan, Chief Medical Officer | 24 Nov 2020 |
| NEW ROLE: Adrian Hinton, Chief Financial Officer | 24 Nov 2020 |
